Searched for
PHARMA REVENUE FORECAST FY27
Pharma sector revenue to grow 11-13 pc in FY27 on strong exports, domestic demand: CrisilIndia's pharmaceutical sector is projected to grow at 11-13 percent this fiscal year due to export increases. The domestic market is also e...- NSE draws brokerage attention on stock market debut as 3 firms initiate coverage on Day 1NSE shares rallied after a muted listing at Rs 1,800, pushing the exchange into India’s ninth-most valued company with a market cap of Rs 4...
- Global agencies see India’s growth ringing louder; raise FY27 GDP forecasts on upbeat demand and investment sentimentIndia’s FY27 growth outlook has received upgrades from the OECD, Asian Development Bank, S&P Global Ratings and Fitch Ratings, with forecas...
- Cupid raises FY27 profit guidance, targets Rs 750 crore revenue; stock up 160% in 2026Cupid Limited raised its FY27 guidance to Rs 725-750 crore revenue and Rs 210-225 crore net profit after strong June-quarter growth. Revenu...
- Budget 2027-28 process begins October 12 with month-long pre-budget meetingsPre-budget meetings for the Union Budget 2027-28 will commence on October 12 and continue until November 13. These discussions aim to final...
- ADB raised India’s FY27 growth forecast to 7%The Asian Development Bank has raised its FY27 India growth forecast to 7% from 6.6%, citing strong public investment and resilience in ser...
- OECD raises India's FY27 GDP growth forecast by 80 bps to 7.1%The OECD has raised its FY27 India growth forecast by 80 basis points to 7.1%, from 6.3% earlier, joining Fitch, S&P Global Ratings and Moo...
- Where's the GDP debate? The world is raising a toast to IndiaIndia’s 7.8% growth has the world taking notice. Fitch, S&P and Moody’s have all raised their forecasts, even as questions over the GDP num...
- After S&P & Fitch, ADB raises India's growth aim to 7% but El Nino clouds food storyIndia's economy is demonstrating resilience, leading to raised growth forecasts from institutions like the Asian Development Bank. However,...
- S&P Global Ratings raises India FY27 growth aim to 7% from 6.6%, estimates 25 bps RBI rate hikeS&P Global Ratings has upgraded its forecast for India's real GDP growth to 7% for the FY27. Strong industrial activity, healthy consumptio...
- India growth seen moderating in second half of FY27 as inflation, liquidity pose risks: DBSIndia's economy may slow in the second half of fiscal 2027. Tighter financial conditions and higher energy prices will impact economic acti...
- Meesho shares rally 12% after UBS hikes target price by 24%. What’s keeping analysts bullish?UBS has raised its Meesho estimates across NMV, contribution profit and EBITDA, citing stronger seller and buyer growth and improving unit ...
- Goldman Sachs raises target on a stock that has already surged over 140% this year. Do you own it?Sansera Engineering shares rallied after Goldman Sachs raised its target price to Rs 4,990 from Rs 4,500 while retaining its Buy rating. Th...
- Ichor Biologics seeks $80-100 million PE funding for minority stake saleIchor Biologics is seeking eighty to one hundred million dollars from private equity investors. The Hyderabad-based company operates in the...
- Moody's raises India's FY27 economic growth forecast to 7% citing resilience, but warns of inflation risksMoody's Ratings increased India's economic growth forecast for fiscal year 2027 to seven percent. The agency cited the nation's resilience ...
- Jefferies hikes Navin Fluorine share price target, forecasts 14% upside. 4 reasons whyJefferies has retained its Buy rating on Navin Fluorine International and raised its price target to Rs 9,405, citing growth prospects in C...
- Moody’s raises India FY27 growth forecast to 7% from 6% on resilient economy, stronger investmentMoody's has raised India's GDP growth forecast to seven percent for 2026-27. Strong private consumption and robust investment are driving t...
- Paytm karo, back in vogue again: Can the stock reclaim IPO price after 5 years and 480% rally?Paytm shares have rebounded over 480% from their lifetime low but remain 20% below the Rs 2,150 IPO price. The introduction of MDR on selec...
- MFs turn selective, pick Coal India, LIC among large-caps in AugustAmid the backdrop of increasing US interest rates in August, fund managers proceeded with caution, prioritizing large-cap stocks that offer...
- JM Financial sees up to 28% upside in Dr Reddy’s and Aurobindo Pharma. Should you buy?JM Financial retained Buy ratings on Dr Reddy’s Laboratories and Aurobindo Pharma, seeing up to 28% upside over the next 12 months. The bro...
Load More
